EP Patent

EP1853266A1 — Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Assigned to Cortendo AB · Expires 2007-11-14 · 19y expired

What this patent protects

Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharaceutically acceptable salts, hydrates, and solvates, that are substantially freee of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 d…

USPTO Abstract

Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharaceutically acceptable salts, hydrates, and solvates, that are substantially freee of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.

Drugs covered by this patent

Patent Metadata

Patent number
EP1853266A1
Jurisdiction
EP
Classification
—
Expires
2007-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Cortendo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.